Conferences

CROI 2022

The Conference on Retroviruses and Opportunistic Infections (CROI) took place from 12 to 16 February. CROI 2022 was held virtually this year due to coronavirus.
CROI 2022
The search for a cure

New York woman is free of HIV 14 months after stem cell transplant

Cancer

Screening and early treatment reduce anal cancer risk by 57% in people living with HIV

Liver disease

Metabolic disorders cause liver damage in people with HIV more often than viral hepatitis in lower-income countries

Bone & joint problems

Better adherence to PrEP is associated with more bone loss

Injectable & long-acting HIV treatment

Injectable cabotegravir plus rilpivirine every two months maintains viral suppression for three years, but carries higher risk of treatment failure

Coronavirus

Long COVID more common in people with HIV

New & experimental HIV treatments

Top 5 HIV treatment stories from CROI 2022

The search for a cure

Top 5 HIV cure and vaccine stories from CROI 2022

Transmission & prevention

Top 5 stories on HIV prevention from CROI 2022

Health problems & ageing

Top 5 stories on HIV, ageing and co-morbidities from CROI 2022

Coronavirus

Top 5 stories on HIV treatment and care in Africa from CROI 2022

PrEP programmes & uptake

Generic PrEP for young, at-risk MSM in the US could be cost-saving and health-enhancing

Antibody-based treatment

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel?

The search for an HIV prevention vaccine

Why did an HIV vaccine fail in the Imbokodo trial?

New & experimental HIV treatments

Lenacapavir shows continued promise for first-line treatment and highly resistant HIV

Injectable & long-acting PrEP

Injected PrEP: breakthrough cases could have been detected sooner

Neurological & cognitive problems

Have HIV-associated neurological disorders declined in people with HIV due to recent antiretrovirals?

Changing treatment

Further evidence that recycling tenofovir in second-line treatment is effective

Pregnancy and vertical transmission

Infant weight and height lower with efavirenz than with dolutegravir in pregnancy

HIV testing programmes & uptake

Virtual approaches boost HIV self-testing in India

HIV treatment for children & young people

Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two years later

Injectable & long-acting PrEP

Injected PrEP: cabotegravir maintains its advantage over four years

HIV testing policies & guidelines

More focused HIV testing in PEPFAR countries yields results

Elimination of hepatitis C

New cases of hepatitis C declining in people with HIV as access to treatment broadens

Vaccinations & immunisations

COVID-19 vaccine rates in people with HIV mirror those in the general population

HIV treatment for children & young people

Point-of-care viral load tests did not improve viral suppression in Kenyan children

Antibody-based treatment

One person remains undetectable without HIV drugs almost four years after using an antibody-based therapy

Vaccinations & immunisations

COVID-19 vaccine booster produces strong responses in people with HIV with low CD4 counts

Cardiovascular disease

Heart attack rates are declining, but not in people with HIV

Epidemiology

Overall lifetime risk of being diagnosed with HIV in the US decreases by 11%, but stark racial and geographical disparities persist

Ageing & HIV

Anticholinergic medications associated with falls and frailty in people ageing with HIV

Coronavirus

COVID-19 raises the risk of adverse birth outcomes, especially in women with HIV

Antibody-based treatment

Could antibodies be used for children with HIV instead of pills?

Coronavirus

Booster vaccine doses protect people with HIV against severe COVID-19

HIV prevention policy

What led to the fall in HIV cases in UK gay men?

Pregnancy and vertical transmission

Zero vertical transmissions from over 5000 pregnant women with undetectable HIV in France

Interviews

CROI 2022: HIV remission after transplant

17 February 2022

At CROI 2022, Professor Yvonne Bryson from the University of California Los Angeles talks about the woman in New York who has no detectable HIV 14 months after stopping antiretroviral therapy following a stem-cell transplant for leukaemia.

CROI 2022: Antibody treatment for children

17 February 2022

Dr Roger Shapiro from Harvard University talks about antibody treatment for children with HIV and could it be used instead of pills at CROI 2022.

CROI 2022: Anal cancer

18 February 2022

At CROI 2022, Professor Joel Palefsky from the University of California San Francisco talks about the ANCHOR trial, which has showed that screening and early treatment reduces anal cancer in people with HIV.

Conference bulletins

English

CROI 2022: New York woman free of HIV 14 months after stem cell transplant, Wednesday 16 February 2022

(HTML)

CROI 2022: Hepatitis C declining in people with HIV as access to treatment broadens, Thursday 17 February 2022

(HTML)

CROI 2022: Screening and early treatment reduce anal cancer in people with HIV, Friday 18 February 2022

(HTML)

CROI 2022: More evidence to support recycling tenofovir in second-line treatment, Wednesday 23 February 2022

(HTML)

French

CROI 2022: Une New-Yorkaise est en rémission de VIH, 14 mois après une greffe de cellules souches, Mercredi 16 février 2022

(HTML)

CROI 2022: L’hépatite C recule chez les personnes séropositives avec l’élargissement de l’accès au traitement, Jeudi 17 février 2022

(HTML)

CROI 2022: Le dépistage et le traitement précoce réduisent les risques de cancer du canal anal chez les personnes séropositives, Vendredi 18 février 2022

(HTML)

CROI 2022: Des données supplémentaires justifient le recyclage du ténofovir en traitement de deuxième intention, Mercredi 23 février 2022

(HTML)

Spanish

CROI 2022: Una mujer de Nueva York, libre del VIH catorce meses después de un trasplante de células madre, Miércoles, 16 de febrero de 2022

(HTML)

CROI 2022: Descenso de los casos de hepatitis C en personas con el VIH al aumentar el acceso al tratamiento, Jueves, 17 de febrero de 2022

(HTML)

CROI 2022: El cribado y el tratamiento precoz reducen las tasas de cáncer anal en personas con el VIH, Viernes, 18 de febrero de 2022

(HTML)

CROI 2022: Más pruebas que respaldan la reutilización de tenofovir en tratamientos de segunda línea, Miércoles, 23 de febrero de 2022

(HTML)

Portuguese

CROI 2022: Mulher em Nova Iorque sem VIH 14 meses após transplante de células estaminais, Quarta-feira, 16 de fevereiro de 2022

(HTML)

CROI 2022: Hepatite C diminui nas pessoas com VIH à medida que o acesso ao tratamento aumenta, Quinta-feira, 17 de fevereiro de 2022

(HTML)

CROI 2022: Rastreio e tratamento precoce reduzem cancro anal em pessoas com VIH, Sexta-feira, 18 de fevereiro de 2022

(HTML)

CROI 2022: Mais evidências apoiam a reutilização do tenofovir no tratamento de segunda linha, Quarta-feira, 23 de fevereiro de 2022

(HTML)

Italian

CROI 2022: La ‘paziente di New York’, in remissione dall’HIV a 14 mesi dal trapianto di staminali, Mercoledì 16 febbraio 2022

(HTML)

CROI 2022: Epatite C in calo tra le persone HIV+ grazie all’aumentato accesso alle terapie, Notizie da CROI 2022

(HTML)

CROI 2022: Screening e trattamento precoce per ridurre il cancro anale nelle persone HIV-positive, Venerdì 18 febbraio 2022

(HTML)

CROI 2022: Ulteriori evidenze a favore del reimpiego del tenofovir nel trattamento di seconda linea, Mercoledì 23 febbraio 2022

(HTML)

Russian

КРОИ 2022: Жительница Нью-Йорка свободна от ВИЧ-инфекции после трансплантации стволовых клеток и через 14 месяцев после прекращения ВААРТ, Среда, 16 февраля 2022 г.

(HTML)

КРОИ 2022: Заболеваемость вирусным гепатитом С снижается среди ВИЧ-инфицированных лиц благодаря расширению доступа к терапии, Четверг, 17 февраля 2022 г.

(HTML)

КРОИ 2022: Скрининг и своевременная терапия предраковых изменений снижает уровень анального рака у ВИЧ-инфицированных лиц, Пятница, 18 февраля 2022 г.

(HTML)

КРОИ 2022: Больше данных в поддержку реутилизации тенофовира в схемах второго выбора, Среда, 23 февраля 2022 г.

(HTML)